Lappa therapeutics email format

Lappa Therapeutics has overcome the problems associated with conventional immunotherapy treatments for melanoma with an innovative solution: a patented microneedle patch that delivers the right amount of immunotherapies where needed in a consistent, sustained, controlled manner. While immunotherapies fight melanoma and are at the forefront of the fight against cancer, Lappa's concept is a substantial improvement over existing alternatives. This solution offers a reduction in side effects, a minimization of patient burden, and an improvement in efficacy. Lappa Therapeutics is the only company to combine two substantiated technologies, microneedle patches and immunotherapies. Because microneedle patches are safely used in other applications and immunotherapies are effective at treating melanoma, Lappa Therapeutics will be able to rapidly deliver its melanoma-fighting patch to market. By taking advantage of FDA-approved checkpoint immunotherapies in combination with FDA-approved microneedle patches, Lappa aims to gain approval, using the FDA's expedited 510k clearance, to its microneedle predicate in an accelerated timeline. To bring this innovation to market, Lappa Therapeutics has assembled a diverse team with decades of experience in biomedical science, business law, medicine, pharmaceutical marketing, and executive-level management. Collocated in Washington D.C., New York City, Baltimore, and Philadelphia, members of the Lappa team have successfully launched advances in medicine while gaining FDA approval. This year, the market for checkpoint immunotherapies for melanoma-type skin cancer has grown to $6 billion in the US, Europe, and Australia alone. Within this rapidly growing market, the team at Lappa is poised to capture 2% of this market within 5 to 10 years after FDA approval. Lappa is dedicated to providing breakthrough cancer treatments. If you are interested in participating in our fight against cancer, we'd love to speak to you more about our project.